- Home
- EXEL vs BBIO Comparison
EXEL vs BBIO Comparison
Compare EXEL & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXEL | BBIO |
|---|---|---|
| Founded | 1994 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 12.7B |
| IPO Year | 2000 | 2019 |
Fundamental Metrics
Financial Performance| Metric | EXEL | BBIO |
|---|---|---|
| Price | $52.70 | $67.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 25 |
| Target Price | $46.50 | ★ $86.33 |
| AVG Volume (30 Days) | 2.4M | ★ 2.8M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.95 | N/A |
| EPS | ★ 0.79 | N/A |
| Revenue | $452,477,000.00 | ★ $502,076,000.00 |
| Revenue This Year | $13.61 | $89.45 |
| Revenue Next Year | $13.13 | $73.78 |
| P/E Ratio | $66.50 | ★ N/A |
| Revenue Growth | N/A | ★ 126.26 |
| 52 Week Low | $33.76 | $38.57 |
| 52 Week High | $52.96 | $84.94 |
Technical Indicators
Market Signals| Indicator | EXEL | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 63.95 | 46.98 |
| Support Level | $40.17 | $62.37 |
| Resistance Level | N/A | $69.85 |
| Average True Range (ATR) | 1.49 | 2.77 |
| MACD | 0.07 | 0.10 |
| Stochastic Oscillator | 96.00 | 46.43 |
Price Performance
Historical ComparisonAbout EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.